ELISA/assay

Rat Antithrombin III (AT3) ELISA Kit

MBS733896

96 Strip Wells

675 USD

ELISA Kit

Rat Antithrombin III (AT3) ELISA Kit

Antithrombin III (AT3)

antithrombin-III; Antithrombin-III; antithrombin-III; serpin C1; antithrombin III; serine-cysteine proteinase inhibitor clade C member 1; serine (or cysteine) proteinase inhibitor, clade C (antithrombin), member 1; serpin peptidase inhibitor, clade C (antithrombin), member 1; Serpin C1

AT3

SERPINC1; SERPINC1; AT3; AT3D; ATIII; THPH7; AT3; ATIII

ANT3_HUMAN

464

Sensitivity: The sensitivity in this assay is 0.1 ng/mL. Specificity: This assay has high sensitivity and excellent specificity for detection of AT3. No significant cross-reactivity or interference between AT3 and analogues was observed.

Store all reagents at 2-8 degree C

For Samples: Cell culture fluid, body fluid, tissue homogenate, serum and blood plasma. Intended Uses: This AT3 ELISA kit is intended for laboratory research use only and not for use in diagnostic or therapeutic procedures. The stop solution changes the color from blue to yellow and the intensity of the color is measured at 450 nm using a spectrophotometer. In order to measure the concentration of AT3 in the sample, this AT3 ELISA Kit includes a set of calibration standards. The calibration standards are assayed at the same time as the samples and allow the operator to produce a standard curve of Optical Density versus AT3 concentration. The concentration of in the samples is then determined by comparing the O.D. of the samples to the standard curve. Principle of the Assay: The coated well immunoenzymatic assay for the quantitative measurement of AT3 utilizes a multiclonal anti-AT3 antibody and an AT3-HRP conjugate. The assay sample and buffer are incubated together with AT3-HRP conjugate in pre-coated plate for one hour. After the incubation period, the wells are decanted and washed five times. The wells are then incubated with a substrate for HRP enzyme. The product of the enzyme-substrate reaction forms a blue colored complex. Finally, a stop solution is added to stop the reaction, which will then turn the solution yellow. The intensity of color is measured spectrophotometrically at 450nm in a microplate reader. The intensity of the color is inversely proportional to the AT3 concentration since AT3 from samples and AT3-HRP conjugate compete for the anti-AT3 antibody binding site. Since the number of sites is limited, as more sites are occupied by AT3 from the sample, fewer sites are left to bind AT3-HRP conjugate. Standards of known AT3 concentrations are run concurrently with the samples being assayed and a standard curve is plotted relating the intensity of the color (Optical Density) to the concentration of AT3. The AT3 concentration in each sample is interpolated from this standard curve.

4502261

NP_000479.1

NM_000488.3

P01008

52,602 Da

Common Pathway 106060!!Complement And Coagulation Cascades Pathway 198880!!Complement And Coagulation Cascades Pathway 83073!!Complement And Coagulation Cascades Pathway 484!!Formation Of Fibrin Clot (Clotting Cascade) Pathway 106057!!Glypican 1 Network Pathway 138010!!Hemostasis Pathway 106028

The protein encoded by this gene is a plasma protease inhibitor and a member of the serpin superfamily. This protein inhibits thrombin as well as other activated serine proteases of the coagulation system, and it regulates the blood coagulation cascade. The protein includes two functional domains: the heparin binding-domain at the N-terminus of the mature protein, and the reactive site domain at the C-terminus. The inhibitory activity is enhanced by the presence of heparin. More than 120 mutations have been identified for this gene, many of which are known to cause antithrombin-III deficiency. [provided by RefSeq, Jul 2009]

Function: Most important serine protease inhibitor in plasma that regulates the blood coagulation cascade. AT-III inhibits thrombin, matriptase-3/TMPRSS7, as well as factors IXa, Xa and XIa. Its inhibitory activity is greatly enhanced in the presence of heparin. Ref.18. Subunit structure: Forms protease inhibiting heterodimer with TMPRSS7. Subcellular location: Secreted extracellular space. Tissue specificity: Found in plasma. Ref.22. Post-translational modification: Phosphorylation sites are present in the extracelllular medium. Involvement in disease: Defects in SERPINC1 are the cause of antithrombin III deficiency (AT3D) [. MIM:613118]. AT3D is an important risk factor for hereditary thrombophilia, a hemostatic disorder characterized by a tendency to recurrent thrombosis. AT3D is classified into 4 types. Type I: characterized by a 50% decrease in antigenic and functional levels. Type II: has defects affecting the thrombin-binding domain. Type III: alteration of the heparin-binding domain. Plasma AT-III antigen levels are normal in type II and III. Type IV: consists of miscellaneous group of unclassifiable mutations. Ref.3 Ref.12 Ref.13 Ref.32 Ref.33 Ref.34 Ref.35 Ref.36 Ref.37 Ref.38 Ref.39 Ref.41 Ref.42 Ref.43 Ref.44 Ref.45 Ref.46 Ref.47 Ref.48 Ref.49 Ref.50 Ref.51 Ref.52 Ref.53 Ref.54 Ref.55 Ref.56 Ref.57 Ref.58 Ref.60 Ref.61 Ref.62 Ref.63 Ref.64 Ref.65 Ref.66 Ref.67. Sequence similarities: Belongs to the serpin family. Mass spectrometry: Molecular mass is 57863 Da from positions 33 - 464. Determined by ESI. Ref.13Molecular mass is 57911 Da from positions 33 - 464. Determined by ESI. Variant Thr-414. Ref.13

96 Strip Wells

675 USD